A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease by Vichinsky, Elliott et al.
A randomised comparison of deferasirox versus deferoxamine
for the treatment of transfusional iron overload in sickle cell
disease
Elliott Vichinsky,
1 Onyinye Onyekwere,
2
John Porter,
3 Paul Swerdlow,
4 James
Eckman,
5 Peter Lane,
5,6 Beatrice Files,
5,6
Kathryn Hassell,
7 Patrick Kelly,
8 Felicia
Wilson,
9 Franc ¸oise Bernaudin,
10 Gian
Luca Forni,
11 Iheanyi Okpala,
12
Catherine Ressayre-Djaffer,
13 Daniele
Alberti,
13 Jaymes Holland,
13 Peter
Marks,
13 Ellen Fung,
1 Roland Fischer,
1,14
Brigitta U. Mueller
15 and Thomas
Coates
16 for the Deferasirox in Sickle
Cell Investigators*
1Children’s Hospital and Research Center,
Oakland, CA,
2Howard University, Washington,
DC, USA,
3University College Hospital, London,
UK,
4Wayne State University School of Medicine,
Detroit,MI,
5EmoryUniversitySchoolofMedicine,
Atlanta, GA,
6Children’s Healthcare, Atlanta, GA,
7University of Colorado Health Sciences Center,
Denver, CO,
8Children’s Hospital Medical Center,
Cincinnati, OH,
9University of South Alabama
MedicalCenter,Mobile,AL,USA,
10Departmentof
Paediatrics, Centre Hospitalier Intercommunal,
Cre ´teil, France,
11Centro della Microcitemia,
Ospedale Galliera, Genoa, Italy,
12St Thomas
Hospital,London,UK,
13NovartisPharmaceuticals
Corporation, East Hanover, NJ, USA,
14University
Medical Centre Hamburg-Eppendorf, Germany,
15Texas Children’s Hospital, Baylor College of
Medicine, Houston, TX, and
16Children’s Hospital
Los Angeles, Los Angeles, CA, USA
Re-use of this article is permitted in accordance
with the Creative Commons Deed, Attribution
2.5, which does not permit commercial
exploitation.
Received 27 September 2006; accepted for
publication 13 November 2006
Correspondence: Elliott Vichinsky, MD,
Children’s Hospital and Research Center at
Oakland, 747 52nd Street, Oakland, CA 94609,
USA. E-mail: evichinsky@mail.cho.org
*See Appendix I for a complete list of
investigators
Summary
Deferasirox is a once-daily, oral iron chelator developed for treating
transfusional iron overload. Preclinical studies indicated that the kidney
was a potential target organ of toxicity. As patients with sickle cell disease
often have abnormal baseline renal function, the primary objective of this
randomised, open-label, phase II trial was to evaluate the safety and
tolerability of deferasirox in comparison with deferoxamine in this
population. Assessment of efﬁcacy, as measured by change in liver iron
concentration (LIC) using biosusceptometry, was a secondary objective. A
total of 195 adult and paediatric patients received deferasirox (n ¼ 132) or
deferoxamine (n ¼ 63). Adverse events most commonly associated with
deferasirox were mild, including transient nausea, vomiting, diarrhoea,
abdominal pain and skin rash. Abnormal laboratory studies with deferasirox
were occasionally associated with mild non-progressive increases in serum
creatinine and reversible elevations in liver function tests. Discontinuation
rates from deferasirox (11Æ4%) and deferoxamine (11Æ1%) were similar. Over
1 year, similar dose-dependent LIC reductions were observed with
deferasirox and deferoxamine. Once-daily oral deferasirox has acceptable
tolerability and appears to have similar efﬁcacy to deferoxamine in reducing
iron burden in transfused patients with sickle cell disease.
Keywords: deferasirox, ICL670, Exjade, sickle cell disease, iron overload.
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received repeated blood transfusions by adulthood (Styles &
Vichinsky, 1994; Wanko & Telen, 2005). Transfusion therapy
is likely to further increase in paediatric patients because of
recent evidence indicating its ability to prevent organ injury
and improve the outcome of complications (Adams et al,
1998; The Optimizing Primary Stroke Prevention in Sickle
Cell Anemia (STOP2) Trial Investigators, 2005). However,
because the body has no physiological mechanism to actively
excrete excess iron, repeated blood transfusions lead to
increased body iron burden, including iron deposition into
the liver, heart and endocrine organs (McLaren et al, 1983).
While studies are limited, progressive iron loading and
subsequent tissue injury in sickle cell disease appears similar
to other transfused populations (Ballas, 2001; Manci et al,
2003; Vichinsky et al, 2005). Guidelines from consensus
conferences have therefore recommended daily treatment
with deferoxamine in iron-overloaded patients (National
Institutes of Health, 2002).
Effective administration of iron chelation therapy has been
limited by the route of its administration. Although deferox-
amine is effective in removing iron from the body, due to very
poor oral bioavailability and a short half-life it must be
administered by subcutaneous or intravenous infusion, usually
over 8–12 h on 5–7 d/week (Porter, 2001). Compliance with
this regimen is often poor (Treadwell et al, 2005). The
availability of a once-daily, oral alternative would potentially
facilitate improved compliance, and thereby reduce morbidity
and mortality from iron overload.
Deferasirox is an orally absorbed iron chelator that has been
developed for the management of transfusional iron overload.
Its safety, tolerability and efﬁcacy in reducing body iron
burden have been demonstrated in patients with b-thalas-
saemia major and in other chronic transfusion-dependent
anaemias (Cappellini et al, 2006). Over a 1-year period,
deferasirox was demonstrated to maintain or reduce body
iron burden in regularly transfused patients who had baseline
liver iron concentration (LIC) values of at least 7 mg Fe/g dry
weight (dw) with an acceptable side effect proﬁle.
Individuals with sickle cell disease often have abnormal
baseline renal function. Therefore, it was of note that
preclinical studies conducted with deferasirox in animals
indicated that a potential target organ of toxicity was the
kidney. High doses of deferasirox were found to be associated
with renal tubular damage in rats and marmosets, particularly
in those that did not have iron overload (Vanorden &
Hagemann, 2006). This effect was felt most likely, but not
deﬁnitively, to be related to the pharmacological effect of
deferasirox chelating iron. Based on these preclinical data,
simple extrapolation of the safety proﬁle of deferasirox from a
population of patients with b-thalassaemia major to individ-
uals with sickle cell disease was not deemed to be appropriate.
In addition, whether or not treatment with deferasirox might
trigger or exacerbate sickle cell crises was unknown. Thus, the
primary objective of this randomised, open-label, phase II trial
was to evaluate the safety and tolerability of deferasirox in
comparison with deferoxamine in this population.
Methods
Study design and patient population
Patient eligibility. Patients with sickle cell disease ‡2 years of
age and with iron overload from repeated blood transfusions
were enroled in this trial. Patients receiving regular blood
transfusions or those sporadically transfused who received at
least 20 units of packed red blood cells or equivalent were
eligible. Prior chelation therapy was permitted but was not
mandatory. The serum ferritin level for entry into the
screening period of this study was ‡1000 lg/l. Patients
eligible for entry into the screening period subsequently had
biosusceptometry performed (see below) in order to determine
that they had a sufﬁciently high body iron burden to be eligible
for treatment on the trial.
Patients were excluded if they had a serum creatinine above
the upper limit of normal (ULN), if they had signiﬁcant
proteinuria (as indicated by a urinary protein:creatinine ratio
of ‡0Æ5 conﬁrmed at two visits), or if they had active hepatitis
B or C. Active hepatitis B was deﬁned as liver function tests
above the normal range, together with a positive antigen
(hepatitis B e antigen, hepatitis B surface antigen) test or
positive IgM core antibody test in conjunction with a negative
hepatitis B surface antibody test. Active hepatitis C was deﬁned
as liver function tests above the normal range in the presence
of a positive hepatitis C antibody test and detectable hepatitis
C RNA levels. Other exclusion criteria were second and third
atrioventricular block, QT interval prolongation, or therapy
with digoxin or similar medications. Treatment with b-
blockers or angiotensin-converting enzyme inhibitors was
permitted. Patients with chelation therapy-associated ocular
toxicity were excluded.
After screening requirements were met and informed
consent was obtained, eligibility based on the presence of iron
overload was conﬁrmed by non-invasive determination of LIC
using Superconducting QUantum Interference Device
(SQUID) biosusceptometry (Brittenham et al, 1982). Patients
receiving simple transfusions needed to have a LIC of ‡2m g
Fe/g dw, and those receiving exchange transfusions needed to
have a LIC of ‡5 mg Fe/g dw at study entry. Biosusceptometry
was performed at three centres under a standardised opera-
tional procedure (Turin, Italy; Hamburg, Germany; Oakland,
USA). For consistency, all SQUID biosusceptometry assess-
ments for a given subject were conducted at the same site.
In vivo LIC values by SQUID biosusceptometry (approxi-
mately wet weight) were converted into dry weight LIC values
using the widely adopted wet-to-dry weight ratio of 3Æ33
(Olivieri & Brittenham, 1997). Studies performed as part of
another clinical trial that was initiated just before the current
trial and completed prior to it found that a more precise
conversion factor of twice the adopted factor was applicable to
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adjusted LIC values are presented unless otherwise noted.
Randomisation. Patients were randomised to receive
deferasirox or deferoxamine in a 2:1 manner. The
randomisation was performed using an interactive voice
response system and was stratiﬁed according to the following
age groups: 2 to <6 years, 6 to <12 years, 12 to <16 years and
16 years and older. The randomisation sequence included
permuted block groups of six patients for each of the three age
strata.
Treatment plan. The study duration was 52 weeks. The initial
24 patients enroled were randomised to receive deferasirox
10 mg/kg or deferoxamine at recommended doses of
20–60 mg/kg based on initial LIC. Subsequently, additional
safety information became available for deferasirox suggesting
a need to modify the starting dose (Cappellini et al, 2006).
Therefore, following the enrolment of the ﬁrst 24 patients, the
study was amended so that all subsequent patients randomised
to deferasirox were dosed at 10–30 mg/kg according to
baseline LIC. Deferasirox was given once daily each morning
as a dispersed solution in water, half-an-hour before breakfast.
The dose of deferasirox was reduced by one dose level and not
re-escalated for patients 15 years and older if serum creatinine
increased >33% above baseline on two consecutive occasions.
For children less than 15 years of age, the dose was only
decreased if these values were also above the age-appropriate
ULN. Deferasirox was interrupted for moderate or severe skin
rash and reinstituted at half the initial dose, and dose
re-escalation was permitted. Deferoxamine was administered
as a slow subcutaneous infusion over 8–12 h using electronic
Microject Chrono
  (Medical Technology, Turin, Italy) infusion
pumps on 5–7 d a week. In order to facilitate comparison of
different schedules, all deferoxamine doses reported were
normalised to administration for 5 d/week (i.e. 50 mg/kg
administered 7 d/week would be reported as 70 mg/kg).
The trial was conducted in accordance with the Declaration
of Helsinki. Institutional Review Board approval was obtained
at each participating institution and written informed consent
was obtained from all patients or guardians prior to partici-
pation in any study procedures. Novartis Pharmaceuticals
Corporation (East Hanover, NJ, USA) coordinated the design
and execution of this trial and contributed to the analysis and
interpretation of the trial data. Novartis Pharmaceuticals
Corporation also collaborated with the external authors to
assist in the development and approval of the manuscript for
publication.
Safety assessments. Laboratory assessments were performed at
least monthly and included complete blood counts with
differential counts. Biochemistry testing included electrolytes,
glucose, liver function tests, gamma-glutaryl-transferase, lactate
dehydrogenase,cholesterol,triglycerides,uricacid,totalprotein,
C-reactive protein, copper and zinc levels. Iron parameters
included total iron, transferrin, transferrin saturation and
ferritin. Urinary testing performed on random collections
included determination of creatinine, total protein and
albumin. Physical examinations, electrocardiograms (ECGs),
audiometry and ophthalmological tests were performed at
baseline,12,24,36and52 weeks.Inpatientslessthan16 yearsof
age, additional assessments included growth velocity and
pubertal stage.
Efﬁcacy assessments. Liver iron concentration was determined
by SQUID biosusceptometry at baseline, 24 and 52 weeks. The
24-week assessment was performed primarily for safety
purposes, and the change in LIC was calculated between
baseline and 52 weeks. Serum ferritin was assessed monthly
during the study and the change was determined using the
baseline and ﬁnal ferritin level.
Compliance. For deferasirox, compliance was assessed by
counting the number of tablets returned in bottles at each
visit. For deferoxamine, the numbers of vials returned at each
visit were counted.
Statistical analysis
The data were analysed under supervision of the trial
statistician and were reviewed by the investigators. The sample
size was calculated based on the number of deferasirox-treated
patients required to detect adverse experiences having an
underlying event rate of at least 4% with 95% conﬁdence,
according to the method of Hanley and Lippman-Hand
(1983). The assessment of safety was based mainly on the
frequency of adverse events and on the number of laboratory
values that fell outside the predetermined ranges. Other safety
data (e.g. ECGs, vital signs and other tests) were considered as
appropriate. All safety data are reported for patients who
received at least one dose of study medication.
The main efﬁcacy endpoint was the change in LIC from
baseline assessed at 52 weeks, adjusted according to the
transfusion category (simple, exchange, simple and exchange).
Descriptive statistics are presented throughout where appro-
priate. Testing for statistical signiﬁcance for differences
between baseline and end-of-study for each treatment group
was performed using Student’s t-test. Using a two-sided test,
P-values <0Æ05 were considered to be statistically signiﬁcant.
Results
Study population
Patients were recruited by investigators at 44 sites in the USA,
France, Italy, UK and Canada. Of the 203 eligible patients
randomised, 195 received treatment and are included in the
safety population. The percentage of patients discontinuing
deferasirox and deferoxamine was similar (11Æ4% vs. 11Æ1%
respectively). Adverse events resulted in discontinuations in
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deferoxamine. The remainder of the discontinuations was due
to patients lost to follow-up, withdrawal of consent and
protocol violations. Six patients randomised to deferasirox and
one patient randomised to deferoxamine withdrew consent.
The reasons for withdrawal of consent were not included in the
database. Three patients randomised to deferoxamine were
unwilling to comply with drug administration and were
discontinued due to protocol violations. Two patients rand-
omised to deferasirox and one patient randomised to defe-
roxamine could not be located for follow-up. The two groups
were well balanced for age, transfusion type and history of
prior chelation therapy (Table I). Baseline LIC and ferritin
values in the two groups were similarly elevated.
Drug administration and compliance
The doses of deferasirox and deferoxamine were based on the
baseline LIC determined by SQUID biosusceptometry conver-
ted by the adopted wet-to-dry weight factor of 3Æ33. The
percentage of patients falling into each dose category was
similar for the two treatment arms (Table II). The mean doses
of deferasirox administered were approximately half those of
deferoxamine. During the study the ratios of the administered
to intended doses of therapy were high (1Æ16 for deferasirox
and 0Æ97 for deferoxamine), indicating high adherence to the
prescribed treatment regimens.
Safety and tolerability
Adverse events, irrespective of the relationship to study
medication, which occurred in more than 10% of patients
receiving either treatment, are shown in Table III. As arbitrar-
ily deﬁned by an increased frequency of at least 5% indicating a
potential relationship to drug administration, adverse events
observed more commonly with deferasirox included abdom-
inal pain, nausea, vomiting, diarrhoea, back pain and skin rash.
Those observed more commonly in patients receiving defe-
roxamine included cough, nasopharyngitis and viral infection.
A similar incidence of several adverse events, such as headache
and upper respiratory tract infection, was observed with both
drugs, indicating a possible relationship to the underlying
disease or to the administration of both drugs.
The gastrointestinal adverse events that patients experienced
with deferasirox were generally transient in nature and lasted
about 1 week maximum. The number of patients receiving
deferasirox and deferoxamine that reported serious adverse
events was similar (46Æ2% and 42Æ9% respectively) and the
most common serious adverse event in both groups was sickle
cell anaemia with crisis (33Æ3% and 31Æ7% respectively).
Haematological parameters were similar in the deferasirox
and deferoxamine groups. Mild, stable increases in serum
creatinine were observed in 36Æ4% and 22Æ2% of patients
receiving deferasirox and deferoxamine respectively. Change in
the mean ± SD (range) creatinine from baseline to end-of-
study was 6Æ30 ± 9Æ00 lmol/l ()8Æ90 to 39Æ80 lmol/l) with
deferasirox and 3Æ06 ± 9Æ43 lmol/l ()17Æ80 to 22Æ10 lmol/l)
with deferoxamine. The number of patients with serum
creatinine values that also exceeded the ULN was similar in
the two groups (2Æ3% and 3Æ2% respectively). Approximately
30% of patients in both the deferasirox and deferoxamine
groups had urinary protein to creatinine ratios of >0Æ2 mg/mg
at baseline, and this percentage did not change measurably in
either group over the course of the study.
Two consecutive alanine aminotransferase (ALT) levels >5·
ULN were observed in ﬁve patients (3Æ8%) treated with
deferasirox and in none treated with deferoxamine. Three of
these individuals treated with deferasirox had at least one ALT
level >5· ULN during the screening period. The elevations
were transient in four patients even with continued drug
administration. In one patient, a persistently elevated ALT led
to interruption of deferasirox therapy. After normalisation of
the ALT level the individual was rechallenged with deferasirox
and the elevation in ALT recurred. Treatment was permanently
discontinued and the ALT returned to normal.
Table I. Patient demographics and selected clinical parameters.
Variable/statistic
Deferasirox
(n ¼ 132)
Deferoxamine
(n ¼ 63)
All patients
(n ¼ 195)
Age, years
Median 15 16 15
Range 3–54 3–51 3–54
Age group, %
<6 years 3Æ04 Æ83 Æ6
6 to <12 years 22Æ72 3 Æ82 3 Æ1
12 to <16 years 25Æ02 0 Æ62 3 Æ6
16 to <50 years 47Æ74 9 Æ24 8 Æ2
50 to <65 years 1Æ51 Æ61 Æ5
Sex, %
Female 60Æ65 5 Æ65 9 Æ0
Race, %
Caucasian 6Æ14 Æ85 Æ6
Black 89Æ49 3 Æ79 0 Æ8
Others 4Æ51 Æ63 Æ6
Ferritin, lg/l
Median 3460 2834 3298
Min–max 1082–12 901 1015–15 578 1015–15 578
Baseline ALT, %
£2Æ5 ULN 83Æ39 2 Æ18 6 Æ2
>2Æ5 ULN 15Æ97 Æ91 3 Æ3
Missing 0Æ8–0 Æ5
History of hepatitis B and/or C, %
Present 7Æ66 Æ37 Æ2
Prior chelation therapy, %
Deferoxamine
or deferiprone
62Æ96 0 Æ36 2 Æ1
Blood transfusions during study (units of packed red blood cells)
Median 12 12 12
Range 0–24 1–22 0–24
ALT, alanine aminotransferase; ULN, upper limit of normal.
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assessed by growth velocity was similar with deferasirox
and deferoxamine. The change in growth velocity in patients
<6, 6 to <12 and 12–16 years was 7Æ1±1 Æ7, 6Æ0±3 Æ2
and 4Æ6±4 Æ0 cm/year, respectively, for those treated with
deferasirox versus 6Æ1±1 Æ9, 4Æ8±2 Æ5 and 3Æ4±3 Æ8 cm/year,
respectively, for those treated with deferoxamine. In addition,
there were no differences in sexual maturity between patients
receiving deferasirox and deferoxamine as assessed by Tanner
stage (Tanner, 1978).
Efﬁcacy
Iron intake was calculated from the total amount of red blood
cells transfused as previously described (Cappellini et al, 2006).
For exchange transfusions, the mg amount of iron removed
was calculated based on the volume of packed red blood cells
removed (1 ml red blood cells removed equals 1Æ08 mg iron).
The mean and median amount of iron administered in the
form of blood transfusions during the study was nearly
identical in patients receiving deferasirox and deferoxamine
(0Æ22 mg/kg/d and 0Æ23 mg/kg/d respectively). The majority of
patients (58Æ5%) received simple transfusions during the
course of the study. The remaining patients received either
exchange transfusions alone (18Æ5%), a combination of simple
and exchange transfusions (21Æ0%), or no transfusions (2Æ1%).
Administration of deferasirox resulted in a statistically
signiﬁcant reduction in LIC for the overall population,
adjusted for transfusion category, of )3Æ0±6 Æ2 mg Fe/g dw
(P <0 Æ001). This was similar to the reduction observed with
deferoxamine for the overall population, adjusted for transfu-
sion category, of )2Æ8±1 0 Æ4 mg Fe/g dw (P ¼ 0Æ022).
Statistically signiﬁcant reductions in LIC at the level of
P <0 Æ05 were observed with treatment at deferasirox doses of
10–30 mg/kg and at a deferoxamine dose of 35 to <50 mg/kg
Table II. Dosing algorithm according to baseline liver iron concentration (LIC) groups (reported and adjusted) and average daily doses adminis-
tered.
Baseline LIC group
Baseline LIC (mg Fe/g dw)
£3 >3–7 >7–14 >14
Deferasirox (n ¼ 132) (n ¼ 4) (n ¼ 64) (n ¼ 46) (n ¼ 18)
Protocol assigned dose 5 mg/kg 10 mg/kg 20 mg/kg 30 mg/kg
Reported mean LIC ± SD* 2Æ5±0 Æ47 Æ9±5 Æ59 Æ8±1 Æ91 7 Æ5±3 Æ0
Adjusted mean LIC ± SD 5Æ0±0 Æ81 5 Æ8±1 1 Æ01 9 Æ6±3 Æ83 5 Æ0±6 Æ0
Deferasirox dose (mg/kg)  9Æ5±3 Æ21 3 Æ0±3 Æ11 9 Æ7±2 Æ12 8 Æ0±2 Æ8
Min–max deferasirox dose 5Æ0–12Æ38 Æ4–23Æ91 0 Æ0–24Æ52 2 Æ8–30Æ0
Deferoxamine (DFO, n ¼ 63) (n ¼ 6) (n ¼ 21) (n ¼ 20) (n ¼ 16)
Protocol assigned dose  20–30 mg/kg 25–35 mg/kg 35–50 mg/kg ‡50 mg/kg
Reported mean LIC ± SD 3Æ9±3 Æ55 Æ2±2 Æ18 Æ6±3 Æ01 4 Æ3±5 Æ4
Adjusted mean LIC ± SD 7Æ8±7 Æ01 0 Æ4±4 Æ21 7 Æ2±6 Æ02 8 Æ6±1 0 Æ8
DFO dose (mg/kg)  22Æ9±3 Æ92 8 Æ7±3 Æ23 6 Æ6±9 Æ55 0 Æ0±7 Æ3
Min–max DFO dose 20Æ0–29Æ52 1 Æ6–34Æ47 Æ0–52Æ63 2 Æ4–62Æ0
Deferasirox/DFO dose ratio 1:2Æ4 1:2Æ2 1:1Æ85 1:1Æ8
*For the reported LIC values a correction factor of 3Æ33 was used to convert the wet weight to dry weight values (Brittenham et al, 1982); for the
adjusted values a correction factor of 6Æ66 was used (Olivieri & Brittenham, 1997).
 Average daily doses are reported for the 1-year period of drug administration. For deferoxamine the reported doses are normalised to those
administered with a 5-d treatment regimen.
 Patients in the two lower LIC groups (LIC £ 3 and >3–7 mg Fe/g dw) who were randomised to treatment with deferoxamine were allowed to
continue on their current deferoxamine dosage, even if this was higher than recommended in this table.
Table III. Percentage of adverse events reported with greater than 10%
frequency in either arm.
Adverse events, %
Deferasirox
(n ¼ 132)
Deferoxamine
(n ¼ 63)
All patients
(n ¼ 195)
Sickle cell anaemia
with crisis
33Æ33 1 Æ73 2 Æ8
Headache 28Æ83 3 Æ33 0 Æ3
Abdominal pain 28Æ01 4 Æ32 3 Æ6
Nausea 22Æ71 1 Æ11 9 Æ0
Pyrexia 21Æ21 7 Æ52 0 Æ0
Vomiting 21Æ21 5 Æ91 9 Æ5
Diarrhoea 19Æ74 Æ81 4 Æ9
Back pain 18Æ25 Æ91 7 Æ4
Upper respiratory tract
infection
18Æ21 9 Æ01 8 Æ5
Arthralgia 15Æ21 4 Æ31 4 Æ9
Pain in extremity 14Æ41 2 Æ71 3 Æ8
Pharyngolaryngeal pain 14Æ49 Æ51 2 Æ8
Cough 13Æ62 0 Æ61 5 Æ9
Nasopharyngitis 13Æ62 0 Æ61 5 Æ9
Rash 13Æ64 Æ81 0 Æ8
Constipation 9Æ81 4 Æ31 1 Æ3
Chest pain 9Æ11 2 Æ71 0 Æ3
Viral infection 4Æ51 1 Æ16 Æ7
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groups of patients enroled into the trial.
Comparing patients who were categorised as only receiving
simple transfusions to those only receiving exchange transfu-
sions, the reductions in LIC observed with deferasirox were
)1Æ6±5 Æ78 mg Fe/g dw (n ¼ 62) and )6Æ6±5 Æ60 mg Fe/g
dw (n ¼ 22) respectively. The corresponding reductions in
patients receiving deferoxamine were )1Æ4±3 Æ12 mg Fe/g dw
(n ¼ 35) and )1Æ4±3 Æ90 (n ¼ 10) respectively.
Changes in serum ferritin between baseline and end-of-
study were dose dependent and generally paralleled the
changes in LIC observed (Fig 2). However, there was notable
intra-patient variability in this parameter during the study. In
the overall patient populations treated with deferasirox and
deferoxamine, the changes observed were )183 ± 1651 lg/l
and )558 ± 951 lg/l respectively.
Discussion
Sickle cell disease results in acute complications and progres-
sive multi-organ failure. Transfusion therapy reduces the
number of erythrocytes containing sickle haemoglobin and
reduces the vascular complications associated with the disease.
In the STOP trial, which recruited asymptomatic children at
risk for cerebral infarction, transfusions resulted in a 90%
reduction in the rate of ﬁrst stroke (Adams et al, 1998). In
addition to preventing primary and secondary stroke in
children, preventative transfusion programmes decrease the
frequency of total hospitalisations, vasoocclusive events, acute
chest syndrome and growth failure (Vichinsky et al, 2005).
Chronic transfusions have been recommended in order to
decrease the morbidity of end-organ failure associated with
heart, pulmonary and renal disease in children and adults
(National Institutes of Health, 2002).
Despite the signiﬁcant beneﬁts that such transfusions may
bring, they result in iron overload that is clearly associated with
morbidity and mortality in b-thalassaemia (Gabutti & Piga,
1996; Schrier & Angelucci, 2005). Evidence is also accumulat-
ing regarding the deleterious effects of iron overload in
patients with sickle cell disease. This transfusion-related
complication is estimated to affect a sizable number of sickle
cell patients (Hagar & Vichinsky, 2000). As indicated by the
baseline LIC and serum ferritin levels of patients enroled into
this clinical trial, patients with sickle cell disease receiving
blood transfusions may have markedly elevated iron burdens.
These levels are similar to those commonly encountered in
b-thalassaemia major and may place them at risk for serious
complications.
This comparative study demonstrated that deferasirox was
reasonably well tolerated in patients with sickle cell disease
who have relatively normal renal and hepatic function. There
was no excess in sickle cell crises or infections when compared
with deferoxamine. Although the absolute magnitude of the
reduction may be under- or overestimated because biosuscep-
tometry using SQUID, rather than liver biopsy, was utilised in
order to determine the change in LIC, similar reductions in
LIC were observed with deferasirox and deferoxamine in the
overall populations and across all age groups. As would be
expected, greater reductions in LIC were observed with
deferasirox in patients receiving exchange transfusions. A
similar trend was not observed with deferoxamine, possibly
reﬂecting the relatively small sample size. Changes in serum
ferritin were somewhat more variable than those observed in
LIC, as would be expected for this parameter in patients with
sickle cell disease (Brittenham et al, 1993).
The most notable adverse events reported were transient
gastrointestinal symptoms and skin rash. The gastrointestinal
symptoms observed might be, at least in part, related to the
presence of lactose in the formulation of deferasirox. Tablets
contain lactose in an approximately 1:1 ratio by weight to the
active drug substance deferasirox. Mild, stable increases in
serum creatinine were observed in a greater percentage of
patients receiving deferasirox than those receiving deferoxam-
ine, although the percentage of patients with serum creatinine
values above the normal range was similar in both groups. A
dose reduction algorithm for increased serum creatinine
resulted in stabilisation or normalisation of this parameter in
Fig 1. Adjusted change (mean ± SD) in liver iron concentration (LIC)
according to assigned treatment category for deferasirox (solid
squares) and deferoxamine (DFO, open squares). Statistically signiﬁ-
cant reductions in LIC were observed with deferasirox in the dose
groups treated with 10 (n ¼ 60), 20 (n ¼ 45) and 30 (n ¼ 14) mg/kg
with P-values of 0Æ001, 0Æ014, and <0Æ001 respectively.
Fig 2. Change (mean ± SD) in serum ferritin according to assigned
baseline liver iron concentration (LIC) category for deferasirox (solid
squares) and deferoxamine (DFO, open squares).
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relatively small percentage of patients, and were not associated
with changes in alkaline phosphatase or bilirubin levels. Such
elevations in ALT may be associated with hepatic iron toxicity
itself (Jensen et al, 2003). However, at least one patient enroled
in this trial did appear to have elevations in ALT that were
caused by deferasirox administration. This conclusion was
based on the isolated recurrence of elevated aminotransferase
upon rechallenge with deferasirox. Drug-induced hepatitis was
not conﬁrmed because the ALT values returned to normal
within a short enough timeframe, so a liver biopsy was not
performed.
Although these data indicate that deferasirox was well
tolerated in individuals with sickle cell disease who had
normal baseline serum creatinine levels, the safety of
deferasirox in sickle cell patients with abnormal serum
creatinine is unknown. Further studies will be required in
this regard. In addition, whereas iron chelation may be
required for many years or even life-long, the duration of
this study was only 1 year. Therefore, long term follow-up
of patients receiving continued treatment is required, and
this is currently ongoing in an extension of the present
study.
Compliance with the administration of parenteral deferox-
amine chelation therapy has proved challenging to all groups
of patients with transfusional iron overload (Cappellini et al,
2006). This is particularly true for patients with sickle cell
disease (Treadwell et al, 2005). Treatment adherence to
therapy in the present study was mandated by the study
protocol and was similar in both treatment groups. However,
in routine clinical practice, compliance with a once-daily, oral
regimen would be expected to be superior to compliance with
a parenteral regimen. Such improved compliance with therapy
should lead to a reduction in morbidity and mortality from
iron overload.
When combined with appropriate laboratory monitoring,
the availability of deferasirox as a once-daily, oral option for
safe and effective chelation therapy has the potential to prevent
complications of iron overload. In paediatric and adult
patients with sickle cell disease this should consequently help
prevent serious complications, such as stroke and organ
failure, by facilitating the appropriate use of blood transfu-
sions.
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